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Abbreviations
!
AIP autoimmune pancreatitis
CP chronic pancreatitis
CT computed tomography
EUS endoscopic ultrasound
FNA fine needle aspiration
FNB fine needle biopsy
GIST gastrointestinal stromal tumor
HCC hepatocellular carcinoma
INR international normalized ratio
NASH nonalcoholic steatohepatitis
NHL non-Hodgkins lymphoma
MRI magnetic resonance imaging
NSCLC non-small cell lung cancer
PDAC pancreatic ductal adenocarcinoma
PET pancreatic endocrine tumor
RCC renal cell carcinoma
SCCA squamous cell carcinoma
SCLC small cell lung cancer
SD standard deviation
TCB Tru-Cut biopsy
Introduction
!
EUS-FNA is widely utilized for cytologic sampling
of endoluminal and extraluminal lesions with a
diagnostic yield approximately of 90%-95% and
an overall sensitivity and specificity of 90% and
100%, respectively [1]. However cytology alone
may have limitations such as obscuring blood, ne-
crotic material, inflammatory cells, or insufficient
material for neoplasms requiring immunocyto-
chemical studies for definitive classification. To
overcome these limitations a spring-loaded 19-
gauge EUS-guided Tru-Cut biopsy (EUS-TCB) de-
vice (Quick-Core, Cook Medical Inc., Winston-
Salem, North Carolina, United States) was devel-
oped in 2002 [2]. EUS-TCB has been shown to pro-
vide core tissue specimens suitable for conven-
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Background and study aims: The optimal core
biopsy needle for endoscopic ultrasound (EUS) is
unknown. The principle aim of this study is to
compare outcomes of EUS-fine-needle biopsy
(EUS-FNB) with a new 19-gauge EUS histology
needle (ProCore, Cook Medical Inc., Winston-
Salem, North Carolina, United States) to a conven-
tional 19-gauge Tru-Cut biopsy (EUS-TCB) needle
(19G, Quick-Core, Cook Medical Inc.).
Patients and methods: Patients referred for EUS
who require possible histologic biopsy were pro-
spectively randomized to EUS-FNB or EUS-TCB.
With the initial needle, ≤3 biopsies were obtained
until either technical failure or an adequate core
was obtained. Patients with suspected inadequate
biopsies were crossed over to the other needle
and similarly ≤3 passes were obtained until ade-
quate cores or technical failure occurred. Techni-
cal success, diagnostic histology, accuracy and
complication rates were evaluated.
Results: Eighty-five patients (mean 58 years; 43
male) were randomized to FNB (n=44) and TCB
(n=41) with seven patients excluded. Procedure
indication, biopsy site, mass size, number of pas-
ses, puncture site, overall technical success and
adverse events were similar between the two
groups. FNB specimens had a higher prevalence
of diagnostic histology (85% vs. 57%; P=0.006),
accuracy (88% vs. 62%; P=0.02), mean total
length (19.4 vs. 4.3 mm; P=0.001), mean com-
plete portal triads from liver biopsies (10.4 vs.
1.3; P=0.0004) and required fewer crossover
biopsies compared to those of TCB (2% vs. 65%;
P=0.0001). Overall technical success and compli-
cation rates were comparable.
Conclusion: EUS-FNB using a 19-gauge FNB nee-
dle is superior to 19-gauge EUS-TCB needle.
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tional histology and with the potential of a higher diagnostic ac-
curacy compared with cytology samples obtained by EUS-FNA
with potentially fewer needle passes [3–7]. However, subse-
quent studies showed an overall diagnostic accuracy for EUS-
TCB of only 55%–75% depending on the site of biopsy [8–11].
Experience with this needle showed potential limitations includ-
ing a stiff, noncompliant sheath and difficult biopsy tray deploy-
ment, particularly with endoscope angulation and a transduode-
nal biopsy approach. Furthermore, the 2cm tray limits use of this
needle to sites smaller than this size.
To overcome the above limitations, a new 19-gauge histology
needle (ProCore, Wilson-Cook Medical Inc., Winston-Salem, NC;
United States) with a “reversed bevel” design was introduced for
EUS-guided fine needle biopsy (EUS-FNB). In the largest study to
date with this new needle including 114 lesions, Iglesias-Garcia
et al. [12] found that EUS-FNB with a 19-gauge needle was tech-
nically feasible in 98%, adequate for full histological assessment
in 89% and produced a sensitivity, specificity, positive predictive
value, negative predictive value, and overall accuracy for diagno-
sis of malignancy of 90%, 100%, 100%, 79%, and 93%, respectively.
While these data appear promising, the performance characteris-
tics of these 19-gauge EUS-FNB and 19-gauge EUS-TCB needles
have not yet been compared.
The aims of this prospective, randomized study were to compare
the diagnostic accuracy (primary endpoint) and the number of
needle passes, total specimen biopsy length, success of immuno-
histochemical labeling and complication rates (secondary end-
points) of the 19-gauge EUS-TCB and the 19-gauge EUS-FNB nee-
dle in patients with a lesion for which a histologic diagnosis is re-
quired. We hypothesized that compared to EUS-TCB, EUS-FNB
would yield a higher diagnostic accuracy, longer biopsy length,
similar immunohistochemical labeling success and complication
rates while requiring fewer biopsies.
Patients and methods
!
Study population
Eligible patients included those referred for EUS at the two parti-
cipating hospitals. The endoscopists at each site reviewed the
medical and imaging records from patients to assess eligibility.
This study was approved by the institutional review boards at
both hospitals and all patients signed informed consent before
enrollment (ClinicalTrials.gov identifier NCT01768325).
Inclusion criteria were patients over 18 years with lesions or
organs measuring at least 2cm in maximal diameter that were
expected to require a histologic diagnosis (i. e. mesenchymal
tumors, granulomatous disease, indeterminate hepatitis, autoim-
mune pancreatitis) or confirmatory immunochemistry to estab-
lish a diagnosis (i. e. pancreatic endocrine tumors). Patients with
a previously nondiagnostic EUS-FNAwithin the previous 60 days
were also considered for enrollment. Exclusion criteria were an
uncorrectable INR >1.5 or platelet <50000, lesions containing a
>25% cystic component, inaccessible lesions proximal to sigmoid
colon or distal to second duodenum, or any previous upper gas-
trointestinal tract or colon surgery. Patients were also excluded if
pregnant, incarcerated, could not independently provide in-
formed consent, or were considered high risk for deep sedation
(American Society of Anesthesiology class IV or V).
Study design
This was a prospective, randomized, double-blinded study invol-
ving two tertiary care teaching hospitals. Randomization was
performed at Indiana University Health Hospital using a comput-
er generated sequence. These sequences were provided to the
study coordinator at each site who concealed allocation for each
patient until after enrollment was signed. Consented patients
were consecutively randomized to either EUS-FNB with a 19-
gauge histology needle (ProCore, Cook Medical Inc., Winston-
Salem, NC; United States) or EUS-TCB with a 19-gauge histology
needle (Quick-Core, Cook Medical Inc., Winston-Salem, NC; Uni-
ted States). Patients and study pathologists were blinded to the
needle utilized. The endoscopist and study coordinators were
not blinded.
Patients underwent up to three biopsies with the initial needle.
The first biopsy was performed and placed either directly in for-
malin or onto filter paper to permit inspection of specimen ade-
quacy. Based on previously published work, adequate specimens
in the current study were considered to have at least 15mm of
tissue for liver biopsies and at least 3mm of tissue for all other
sites [13–15]. If inspection revealed an inadequate specimen, up
to two additional passes were made with the initial needle. If
three passes did not retrieve an adequate specimen or if there
was technical failure during any part of the sampling process pro-
hibiting further biopsies, patients were crossed over to undergo
up to three passes with the other needle. No touch preps or crush
smears were prepared from the core biopsies. Rescue FNAwith a
19-, 22-, or 25-gauge needle and on-site pathology review with
cell block preparationwas permitted if both needles were consid-
ered to yield visibly inadequate specimens on visual inspection
and the endoscopist believed that cytology could provide an ade-
quate tissue diagnosis.
EUS biopsy technique
All procedures were performed by or under the supervision of
one of four experienced attending endosonographers. Examina-
tion was initiated in select patients with an Olympus GF-UE160
radial echoendoscope (Olympus America, Inc.; Center Valley,
Pennsylvania, United States). Curvilinear array endosonography
then was performed using the Olympus GF-UC140P or GF-
UC160-AL5 (Olympus America, Inc.) endoscope.
To perform EUS-TCB, the 19-gauge biopsy device was initially
placed in the “firing position,” and the needle assembly was ad-
vanced through the accessory channel of the endoscope. The le-
sion was punctured and the tray was advanced by depressing
the plunger on the proximal side of the needle. EUS-FNBwas per-
formed initially with the stylet in place. After lesion puncture, the
stylet was completely removed, 10mL of suction was applied for
30 seconds while the needle is stationary with the target, the
needle was then moved several times within the target, suction
disengaged and then the needle was removed. The stylet was
not reinserted for any additional FNB passes. EUS-TCB core biopsy
specimens were retrieved by exposure of the tissue tray while
FNB specimens were procured by either blowing air or reinser-
tion of the stylet through the proximal end of the needle.
Pathology
Core biopsy specimens were immediately placed in formalin and
subsequently embedded in paraffin. Tissue blocks were stained
by hematoxylin end eosin (H&E) and additional immunohisto-
chemistry was performed as needed. Each specimen was exam-
ined by one experienced gastroenterology pathologist at each
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hospital blinded to the needle type. Specimens were assessed for
total specimen length and for adequacy to provide both a histo-
logic diagnosis and desired immunohistochemical studies. Cytol-
ogy specimens if required were interpreted by a cytopathologist
separate from the pathologist who interpreted the core biopsy.
Follow up after biopsy
Patients were monitored in a recovery unit for at least two hours
after EUS for any adverse events. Post-procedure antibiotics were
given at the discretion of the endoscopist. Patients were contac-
ted by telephone at 24 hours, 7 days and 30 days to ascertain and
document any adverse events. Adverse events were categorized
as: 1) related to either needle malfunction alone or; 2) all other
causes and were classified according to a published lexicon [13].
Decisions for surgery or additional testing were made jointly by
the referring physician and the patient based on information
from EUS, biopsy results, clinical diagnosis, and fitness for sur-
gery. If surgery or additional studies were performed, the type
of operation, intraoperative findings and results were recorded.
Study definitions
Technical success with any attempted biopsy was defined as suc-
cessful completion of all steps from needle insertion into the en-
doscope accessory channel to tissue procurement. Inability to
complete any step within was defined as technical failure for
that attempted biopsy. In the absence of surgical resection, diag-
nostic histology (with immunohistochemistry if performed)
provided by FNB or TCB was considered the gold standard.
When diagnostic histology or cytology was not available, a defi-
nitive diagnosis was established on the basis of long-term follow
up, surgery, or further procedures of biopsy. A suspected benign
diagnosis was confirmed by clinical follow up (≥6 months) and
other imaging tests to ensure that no malignancy developed.
Statistical analyses
Based on the previously published studies [6, 12,14] that demon-
strated the diagnostic accuracies of the 19-gauge ProCore and 19-
gauge Quick-Core needles at 92.9% and 61%–68.4%, respectively,
we assumed that the diagnostic accuracy of EUS-FNB and EUS-
TCB is 95% and 65%, respectively. A total sample size of 76 pa-
tients (each group, 38 patients) was therefore required to detect
a significant difference in the proportion of cases between two
groups with α>0.05 and 80% power, allowing for a crossover
rate of 15% for EUS-TCB and 5% for EUS-FNB.
Categorical parameters including gender, location of masses,
technical success and diagnostic accuracy were compared by
χ2-test or Fisher’s exact test while diagnostic accuracy of FNB
compared toTCBwas evaluated with the McNemar’s test. Contin-
uous variables including age, size of mass, follow-up period, nee-
dle passes and adequacy of specimens were compared by the Stu-
dent’s t-test or Wilcoxon rank sum test. For all calculations, biop-
sies with technical failures or insufficient specimens were con-
sidered nondiagnostic biopsies. Diagnostic accuracy for each
group was considered the total diagnoses with immunostains (if
relevant) correct divided by the total number of patients in that
group.All statistical analyses will be performed using SPSS soft-
ware (version 15.0; SPSS, Chicago, IL), with results considered
significant at P values <0.05.
Results
!
Between February 2012 and September 2013, 85 patients were
screened and 85 were consented and randomized to EUS-FNB
(n=44) or EUS-TCB (n=41). Seven patients were excluded includ-
ing three FNB patients (two without identifiable lesions by EUS
and one with a cystic mass) and four TCB patients (two without
identifiable lesions by EUS, one with size<2cm, one with a cystic
mass). The remaining 78 were biopsied with FNB (n=41) or TCB
(n=37). Age, gender, procedural indication, biopsy site, number
of passes performed and successful attempted immunohisto-
chemistry were similar between the two groups (●" Table 1).
Overall size of the mass biopsied was also similar for each group;
10 patients in each group had no mass.
First pass technical success was higher for FNB (95%) compared
to TCB (78%; P=0.041); technical success for subsequent passes
and overall success were equivalent. Diagnostic histology was
higher for FNB (85%) compared to TCB (57%; P=0.006). Similarly,
diagnostic accuracy was higher for FNB (88%) compared to TCB
(62%; P=0.02). For patients undergoing liver biopsy, more mean
complete portal triads were present in specimens acquired by
FNB (10.4±4.7) compared to TCB (1.3±1.9; P=0.0004). When ca-
tegorized by site of puncture (●" Table 2), transduodenal FNB
technical success was higher (100%) compared to TCB (14%; P=
0.02) but similar using a transesophageal (100% vs. 100%; P=
1.0) or transgastric (92% vs. 82%; P=0.11) approach. Compared
to TCB, diagnostic FNB histology was obtained more frequently
using a transgastric (87% vs. 56%; P=0.03) and transduodenal ap-
proach (100% vs. 20%; P=0.047) but was similar when obtained
through the esophageal wall (71% vs. 83%; P=1.0)
Fewer patients randomized to FNB (1/41; 2%) required crossover
to the other needle compared to patients undergoing TCB (24/37;
65%; P=0.001;●" Table 3). One patient undergoing FNB crossed
over to TCB due to the inadequate protrusion of the needle from
the sheath during attempted biopsy. Histology from TCB in this
patient was nondiagnostic, twenty-four TCB patients were cros-
sed over to FNB due to: a visible core of inadequate length (n=9),
no visible core (n=7) or inability to perform a biopsy (n=8). In
these last eight patients, one or more biopsies in each patient
were not possible due to: inability of the needle to exit the sheath
(n=5), inadequate force to biopsy leaving the needle to only
“push” the mass away (n=2) and no adequate angle to perform
biopsy (n=1). Overall diagnostic histology from FNB was seen in
19/24 (79%) of patients crossed over from TCB. The final diagno-
ses for patients in each group are shown in●" Table 4.
Rescue EUS-FNA was performed in one patient initially random-
ized to FNB. In this patient with a retroperitoneal mass after right
nephrectomy, neither FNB nor TCB retrieved visible tissue and
pathology from both were nondiagnostic. EUS-FNA in this pa-
tient was diagnostic for fat necrosis.
Seven patients randomized to TCB underwent EUS-FNA. One pa-
tient with a left adrenal mass had no visible tissue with TCB. Both
FNB and FNA showed benign adrenocortical cells. In the second
patient, diagnostic histology and cytology from FNB and FNA for
lymphoma were obtained after a technically unsuccessful TCB of
a porta hepatis lymph node. In the third patient with a pancreatic
tail mass following nephrectomy, TCB retrieved suspected insuf-
ficient material however TCB and EUS-FNA were diagnostic for
metastatic renal cell carcinoma while FNB was nondiagnostic. In
the fourth patient, both TCB and FNA were diagnostic for a reac-
tive lymph node but FNB was nondiagnostic. In the fifth and sixth
patients, TCB, FNB and FNA of amediastinal lymph node and pan-
DeWitt John et al. Endoscopic ultrasound-guided core biopsy… Endosc Int Open 2015; 03: E471–E478
Original article E473
THIEME
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
creatic headmass were all nondiagnostic. In the final patient, TCB
of an antral subepithelial mass was nondiagnostic but FNB and
FNA both showed acinar epithelium consistent with a pancreatic
rest.
All patients were followed for a minimum of 6 months. The prev-
alence of adverse events related to the FNB needle malfunction
(1/41; 3%) was similar to TCB needle malfunction (2/37; 5%; P=
0.6;●" Table 5). In one patient with suspected type 2 autoim-
mune pancreatitis undergoing FNB of the tail of the pancreas,
the needle would not retract into the sheath (likely from elevator
deflection of the needle into a fibrotic gland) after the first at-
tempted biopsy (●" Fig.1a–d). The endoscope and unretracted
needle were removed together from the pancreas and out of the
patient. Immediate reinsertion of the echoendoscope demon-
strated retroperitoneal hemorrhage in the left upper quadrant
which was confirmed by CT scan the same day (●" Fig. 1b–d).
The patient had mild shoulder pain and was discharged less
Table 1 Comparison between
initial uses of randomized core
biopsy needles.
FNB
(n=41)
TCB
(n=37)
P value
Age
Mean± SD 56.93± 16.33 59.86± 15.79 0.42
Gender, (n, %) 24 (59) 15 (41) 0.17
Indication for biopsy
Liver biopsy 5 (12) 8 (22)
Mesenchymal tumor 9 (22) 4 (11)
Chronic or autoimmune pancreatitis 5 (12) 2 (5)
NHL or sarcoidosis 5 (12) 6 (16) 0.32
Non-diagnostic FNA 1 (3) 4 (11)
Solid tumor or mass 16 (39) 13 (35)
Site of biopsy
Pancreatic head/uncinate 4 (10) 5 (13)
Pancreatic neck/body/tail 7 (17) 5 (13)
Left lobe liver 7 (17) 8 (22)
Gastric wall/mass 7 (17) 5 (13) 0.99
Esophageal wall 1 (3) 1 (4)
Posterior mediastinal node/mass 5 (12) 5 (13)
Abdominal node/mass 10 (24) 8 (22)
Size of mass (mm)
Mean± SD 43.7 ± 26.7 43.0 ± 17.9 0.89
No mass 10 (24) 10 (27)
Number of passes
Mean± SD 2.07 ± 0.72 2.14 ± 0.95 0.71
Median (range) 2 (1–3) 2 (0–3)
Site of puncture
Transesophageal 7 (17) 6 (16) 0.85
Transgastric 30 (73) 25 (71)
Transduodenal 4 (10) 5 (13)
Technical success initial needle (n,%)
First pass 39/41 (95) 29/37 (78) 0.04
Second pass 31/33 (94) 25/27 (93) 1.0
Third pass 10/11 (91) 19/21 (90) 1.0
Overall 80/85 (94) 73/85 (86) 0.12
Diagnostic histology (n,%) 35/41 (85) 21/37 (57) 0.006
Diagnostic accuracy (n, %)1 35/40 (88) 23/37 (62) 0.02
Diagnostic Attempted Immunohistochemistry 24/26 (92) 9/10 (90) 1.0
Overall Specimen Length (mm)
Mean± SD 19.4 ± 14.1 4.3 ±4.5 0.001
Median (range) 15 (3–60) 3 (0–14)
Complete Portal Triads
Number of Patients 5 8 ..
Mean ± SD 10.4 ± 4.7 1.3 ± 1.9 0.0004
Abbreviations: FNB, fine needle biopsy; NHL, non-Hodgkins lymphoma; SD, standard deviation; TCB, Tru-Cut biopsy.
1 Diagnostic Accuracy for FNB group calculated out of 40 patients. One patient lost to follow up and final diagnosis was unconfirmed.
Table 2 Comparison of technical success and diagnostic histology by punc-
ture site for randomized core biopsy needles.
FNB TCB P value
Site of puncture (n, %)
Transesophageal 7/41 (17) 6/37 (16) 0.85
Transgastric 30/41 (73) 25/37 (71)
Transduodenal 4/41 (10) 5/37 (13)
Technical success (n, %)
Transesophageal 16/16 (100) 16/16 (100) 1.0
Transgastric 59/64 (92) 51/62 (82) 0.11
Transduodenal 5/5 (100) 1/7 (14) 0.02
Diagnostic histology (n, %)
Transesophageal 5/7 (71) 5/6 (83) 1.0
Transgastric 26/30 (87) 15/25 (56) 0.03
Transduodenal 4/4 (100) 1/5 (20) 0.047
Abbreviations: FNB, fine needle biopsy; TCB, Tru-Cut biopsy.
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Table 3 Technical success and
diagnostic yield of after crossover
core biopsy required.
Initial FNB (n=41) Initial TCB (n=37) P value
Crossover required to other needle 1 (2.4) 24 (65) 0.0001
Technical success of crossover needle (n, %)
First pass 0/1 (0) 24/24 (100)
Second pass 0/1 (0) 11/11 (100)
Third pass 0/1 (0) 6/6 (100)
Overall 0/1 (0) 41/41 (100)
Diagnostic histology (n, %) 0 (0) 19/24 (79)
Diagnostic Attempted Immunohistochemistry 0 (0) 12/13 (92)
Overall Specimen Length (mm)
Mean ± SD 0 14.5 ± 9.9
Liver biopsy portal tracts
Number performed 0  5
Complete portal tracts (Mean ± SD) 4.6 ± 3.4
Partial portal tracts (Mean ± SD) 3 ± 2.24
Abbreviations: FNB, Fine needle biopsy; TCB, Tru-Cut biopsy.
Table 4 Final clinical diagnoses
in the FNB and TCB groups by site
biopsied.
Diagnosis by site biopsied FNB (n=41) TCB (n=37)
Abdominal node/mass Left adrenal (2) Left adrenal (4)
Metastatic HCC (1) Metastatic NSCLC (1)
Metastatic NSCLC (1) Metastatic SCCA (1)
Benign adrenal (2)
Portahepatis lymph node (5) Portahepatis lymph node (3)
Metastatic GIST (1) NHL (2)
NHL (1) Metastatic duodenal cancer (1)
Granulomatous disease (2)
Metastatic SCLS (1)
Retroperitoneal mass (3) Celiac lymph node (1)
Metastatic thymoma (1) Metastatic ovarian cancer (1)
NHL (1)
Postoperative fat necrosis (1)
Pancreatic head/uncinate PDAC (3) PDAC (2)
CP (1)
PET (1)
NHL (1)
Pancreatic neck/body/tail PDAC (2) PDAC (2)
CP (3) CP (1)
AIP (1) AIP (1)
Normal pancreas RCC (1)
Left lobe liver NASH without fibrosis (3) Nonspecific hepatitis (3)
Steatosis (1) NASH without fibrosis (2)
Normal liver (1) NASH with early fibrosis (1)
Metastatic breast cancer (1) NASH with cirrhosis (1)
Unknown (1) Biliary cirrhosis (1)
Gastric wall/mass Leiomyoma (5) GIST (2)
GIST (2) Leiomyoma (1)
NHL (1)
Pancreatic rest (1)
Posterior mediastinal lymph node or mass Mediastinal mass (4) Subcarinal node (5)
NHL (1) Reactive node (3)
NSCLC (1) NHL (2)
Suggestive of NHL (1) Metastatic NSCLC (1)
AML (1)
Paraesophageal node (2)
Metastatic melanoma (1)
Unknown (1)
Esophageal wall Leiomyoma (1) Leiomyoma (1)
Abbreviations: FNB, fined needle biopsy; TCB, Tru-Cut biopsy; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer;
GIST, gastrointestinal stromal tumor; SCLC, small cell lung cancer; NHL, non-Hodgkin’s lymphoma; SCCA, squamous cell carcinoma;
PDAC, pancreatic ductal adenocarcinoma; CP, chronic pancreatitis; PET, pancreatic endocrine tumor; AIP, autoimmune pancreatitis;
RCC, renal cell carcinoma; NASH, nonalcoholic steatohepatitis.
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than 24 hours later without requiring blood transfusion. Pathol-
ogy from FNB demonstrated chronic pancreatitis without evi-
dence of autoimmune pancreatitis. Two patients with TCB had
adverse events related to the needle. In the first, the distal 2cm
of the needle broke off inside the patient during plunger depres-
sion of the needle during the first attempted transduodenal biop-
sy of a pancreatic head mass (●" Fig. 2a–e). The residual needle
fragment was not visible with white light endoscopy but was
confirmed by repeat EUS and non-contrast CT. After surgical con-
sultation, the patient was discharged to home. Six weeks later the
patient underwent pancreatoduodenectomy for treatment of the
pancreatic mass and removal of the needle fragment. Pathology
from surgical resection confirmed chronic pancreatitis. The sec-
ond patient with an adverse event related to the TCB needle had
the sheath-needle assembly break off at the accessory channel
during biopsy of a pancreatic head mass. Pathology diagnosis
from this first and only TCB pass as well as both crossover FNB
biopsies demonstrated PET.
The frequency of overall adverse events (needle malfunction and
all others) were similar at 24 hours and 30 days (P=1.0 for both).
All were classified as mild in severity [13]. Apart from the patient
with retroperitoneal bleeding, all complications were managed
successfully as outpatients and resolved within 48 hours.
Discussion
!
In the current study, we found that 19-gauge EUS-FNB (ProCore,
Cook Medical Inc., Winston-Salem, NC; United States) provided a
higher prevalence of diagnostic histology, accuracy and overall
specimen length compared to 19-gauge EUS-TCB (Quick-Core,
Cook Medical Inc., Winston-Salem, NC, United States) needle in
patients with either a previously nondiagnostic FNA or a suspect-
ed clinical diagnosis that required histopathology. These results
were achieved despite similar procedure indications, sites of
transmural puncture and mean number of passes between the
two groups. EUS-FNB was technically feasible in 94% of patients
with diagnostic histology in 85%. These results are very similar to
those recently published by Iglesias-Garcia et al. [12] who report-
ed that EUS-FNB with a 19-gauge needle in 114 patients was
technically feasible in 98% and adequate for full histological as-
sessment in 89%. Therefore, procurement of histologic specimens
with the TCB needle used in this study is not recommended.
The 19-gauge EUS-TCB needle has a relatively stiff sheath which
renders transduodenal biopsy very difficult [11,15]. For these
reasons, some previous studies evaluating this needle have lim-
ited sampling to transesophageal or transgastric punctures [18,
19]. In fact, transgastric sampling with this needle appears to in-
Table 5 Complications between initial use of randomized fine-needle and
Tru-Cut biopsy needles.
FNB
(n=41)
TCB
(n=37)
P value
Related to needle (n, %) 1 (3) 2 (5) 0.60
Overall at 24 hours (n, %) 3 (8) 3 (8)
Abdominal pain 1 (3) 2 (5)
Melena 0 (0) 1 (4) 1.0
Retroperitoneal bleeding 1 (3) 0 (0)
Nausea/vomiting 1 (3) 0 (0)
Overall at 2–30 days, (n, %) 2 (5) 3 (8)
Abdominal pain 0 (0) 2 (4) 1.0
Melena 0 (0) 1 (4)
Fever 1 (3) 1 (4)
Nausea/vomiting 1 (3) 0 (0)
Abbreviations: FNB, fine needle biopsy; TCB, Tru-cut biopsy.
Fig.1 Endoscopic ultrasound fine needle biopsy
with a 19-gauge needle (ProCore; Cook Medical Inc,
Winston-Salem, North Carolina, United States) of
the tail of the pancreas in a 27-year-old male with
suspected type 2 autoimmune chronic pancreatitis.
a The needle is seen within the pancreatic parench-
yma. After the initial biopsy, the needle would not
retract into the sheath. The endoscope and the un-
retracted needle were removed together from the
pancreas and out of the patient. b Linear endo-
scopic ultrasound view immediately after removal
of the endoscope and unretracted needle. A retro-
peritoneal hemorrhage in the left upper quadrant
between the spleen and the stomach is noted.
c Axial CT scan demonstrating retroperitoneal he-
morrhage. d Coronal CT scan demonstrating retro-
peritoneal hemorrhage.
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crease diagnostic yield compared to biopsies obtained from other
sites including the duodenum [10]. The novel 19-gauge FNB nee-
dle used in the current study, however was recently reported to
be feasible in 33/35 (94%) of consecutive transduodenal biopsies.
Similarly, we found that EUS-FNB through the duodenum was
technically successful in all five attempted biopsies and yielded
diagnostic histology in all four patients which translated to a
higher technical success and diagnostic yield of transduodenal
biopsy compared to TCB. Recently, Varadarajulu et al [20] found
that transduodenal biopsy using a flexible 19-gauge needle (Bos-
ton-Scientific, Natick MA; United States) was technically feasible
in all 32 patients attempted and a core specimen and histologic
sample acquired in most patients. Whether this new flexible
needle offers any advantage over the FNB needle used in our
study is unknown and merits investigation.
EUS-guided biopsy with a 19-gauge needle has generally been
considered safe with a reported adverse event rate of 2%–4% for
TCB [3–10]. In the largest prospective series to date (n=247)
with 19-gauge EUS-TCB, Thomas et al. reported adverse event
rate of 2.4% [10], in the largest prospective study to date (n=
114) with a 19-gauge FNB needle, Iglesias-Garcia et al. [12] re-
ported no adverse events. In our study, adverse events at 30
days from EUS-TCB (n=37) and EUS-FNB (n=41) were 8% and 5
%, respectively and statistically similar between the two groups.
Hospital admissionwas required for only one patient for 23 hours
for a self-limited retroperitoneal hemorrhage after EUS-FNB of
the tail of the pancreas for suspected autoimmune pancreatitis.
In another patient undergoing transduodenal TCB of the pancre-
atic head, fracture of the needle occurred during depression of
the plunger. Factors contributing to this adverse event included:
the long position of the endoscope, difficult plunger depression,
slight elevator use and acute angle of the needle into the pancre-
atic head. The patient was discharged after endoscopy and the
needle was removed uneventfully during surgery six weeks later.
To our knowledge these two adverse events (retroperitoneal he-
morrhage and needle fracture) after 19-gauge core biopsy have
not been reported to date.
Our study employed a prospective, randomized design with a
single pathologist at each institution to assess the diagnostic ac-
curacy and technical yield of these two needles. Nevertheless re-
sults of our study are limited due to inclusion of patients who
only required histologic diagnoses or previously nondiagnostic
cytology samples. Therefore results of cytology samples acquired
by these two groups were not assessed and may not be compar-
ed. In addition, the criteria utilized for real-time determination of
adequate histology is somewhat subjective. Measurements of
specimen length may have varied among the operators or been
compromised by the amount of blood present within the ac-
quired specimen. Despite these limitations we believed that pre-
set criteria were important to determine when specimens were
adequate and no additional biopsies were required.
In conclusion, EUS-FNB specimens from a 19-gauge needle have a
higher prevalence of diagnostic histology, accuracy and specimen
length but similar overall technical success and rate of adverse
events compared to the 19-gauge EUS-TCB needle. Therefore,
procurement of histologic specimens with the TCB needle used
in this study is not recommended. Future studies evaluating the
diagnostic histology and accuracy of the 19-gauge FNB needle to
a new flexible 19-gauge needle are warranted.
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Fig. 2 EUS.a Linear endoscopic ultrasound de-
monstrating a 6 x 5cm hypoechoic, well defined
mass in the head of the pancreas. b Endoscopic
ultrasound with Tru-Cut biopsy using a 19-gauge
needle (Quick-Core; Cook Medical, Inc.; Winston-
Salem, North Carolina, United States) of the pan-
creatic head mass. c Endoscopic ultrasound exam
after needle fracture showing 2.7cm of the needle
within the pancreatic head. d Picture of the frac-
tured needle protruding through the sheath.
e Non-contrast axial CT demonstrating the frac-
tured needle within the pancreatic head. After
surgical consultation, the patient did not require
hospitalization. The needle was removed unevent-
fully during pancreatoduodenectomy six weeks
later. Pathology demonstrated chronic pancreatitis
without malignancy.
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